Melanoma-Specific Survival Longer With Nivolumab Plus Relatlimab Combined Treatment
Source: Drug Topics, June 2023
Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.
Patients with melanoma who received treatment with nivolumab plus relatlimab had higher rates of progression-free survival and overall survival compared with patients treated only with nivolumab, according to research presented at the 2023 ASCO Annual Meeting.
Investigators conducted a clinical trial to determine if nivolumab plus relatlimab treatment demonstrated a statistically significant progression-free survival benefit compared to treatment with nivolumab alone. Data was gathered from the RELATIVITY-047 (NCT03470922) study with an additional 2 year follow-up.